Sgs Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.75 Cr
- Paid Up Capital ₹ 1.30 Cr
- Company Age 23 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 15.22 Cr
- Revenue Growth 20.29%
- Profit Growth 30.69%
- Ebitda 3.29%
- Net Worth 15.67%
- Total Assets -5.54%
About Sgs Pharmaceutical
Sgs Pharmaceutical Pvt Ltd (SPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 08 May 2001 and has a history of 23 years and nine months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.75 Cr and a paid-up capital of Rs 1.30 Cr.
The company currently has active open charges totaling ₹15.22 Cr.
Nimish Gupta and Manvendra Singh serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24239DL2001PTC110738
-
Company No.
110738
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 May 2001
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Sgs Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nimish Gupta
|
Director | 20-Feb-2007 | Current |
|
Manvendra Singh
|
Director | 30-Jan-2019 | Current |
Financial Performance of Sgs Pharmaceutical.
Sgs Pharmaceutical Pvt Ltd, for the financial year ended 2021, experienced significant growth in revenue, with a 20.29% increase. The company also saw a substantial improvement in profitability, with a 30.69% increase in profit. The company's net worth Soared by an impressive increase of 15.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sgs Pharmaceutical?
In 2021, Sgs Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹15.22 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 14.87 Cr
- Hdfc Bank Limited : 0.35 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Oct 2020 | Hdfc Bank Limited | ₹3.50 M | Open |
| 04 Jan 2006 | State Bank Of India | ₹1.00 Cr | Open |
| 04 Jan 2006 | State Bank Of India | ₹10.51 Cr | Open |
| 04 Jan 2006 | State Bank Of India | ₹3.36 Cr | Open |
How Many Employees Work at Sgs Pharmaceutical?
Sgs Pharmaceutical has a workforce of 55 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sgs Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sgs Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
